The previously unknown stamp of the Covid-19 and unprecedented health protection measures related to it have given a serious impetus to pharmaceutical companies’ innovative development. Within a year, the pharmaceutical business entered the top of corporations’ global rating, actively succeeding in various innovations. This was stated by the head of the Board of Directors of Darnytsia Group, Dmytro Shymkiv.
He also noted that the challenges faced by all countries in recent years stimulated pharmaceutical companies to seek and implement new creative ideas. So, for example, the world-famous Moderna began to use mRNA technology and genome sequencing to produce its vaccine against coronavirus. A few years ago, such innovations were just things to dream about.
In terms of Darnytsia, Dmytro Shymkiv assured that the process of implementing new technologies is constantly being carried out at the factory and affects absolutely all areas of production: from developments in scientific laboratories to deliveries to sales outlets. This business approach has allowed the pharmaceutical concern to become the domestic pharmaceutical market leader and sell the largest volume of products among Ukrainian manufacturers.
In addition, Shymkiv emphasized that the Ukrainian pharmaceutical sector has successfully operated on the global market for a long time. It also should be noted that international healthcare services put forward rather strict requirements regarding the quality of imported medicines. Despite the rather skeptical attitude of the Ukrainian consumer towards domestic medicines, Europeans are pleasantly surprised by our medicines’ high-tech production and highly appreciate their quality. Currently, the Darnytsia factory has 14 production lines certified according to the GMP standard.
The head of the Board of Directors of Darnytsia Group believes that this business model allows exporting domestic drugs to 16 countries globally and regularly expanding its range of products, which today includes more than 260 items.